Epigenetic modifications control gene expression via mechanisms that are highly coordinated throughout the life of a cell. In addition to regulating the development of distinct cell lineages, epigenetic modifications can also promote malignant transformation and cancer progression 1 . Methylation of a CpG site within or near a gene can change its expression, usually by suppressing it. If this happens to a tumor-suppressor gene, oncogenesis may occur 2 . The mechanisms by which aberrant methylation occurs, and its consequences in cancer, are becoming better understood. One such mechanism involves point mutations in isocitrate dehydrogenases 1 and 2 (collectively "IDH mut "). These metabolic enzymes normally convert isocitrate into α-ketoglutarate, but mutations in key arginine residues that normally bind isocitrate substrate cause a radical change in enzymatic activity, wherein mutant enzyme converts α-ketoglutarate into D-2-hydroxyglutarate (D2HG) 3 . D2HG then acts as a competitive inhibitor of other enzymes that require α-ketoglutarate as a cofactor, including certain DNA demethylases, leading to genomic CpG hypermethylation and globally altered transcription 4, 5 . IDH mut -induced hypermethylation may lead to suppression of cellular differentiation, thereby prolonging the window in which additional oncogenic "hits" can occur 6 . IDH mut has been identified in a variety of malignancies, but the most common include infiltrative glioma 7 , acute myeloid leukemia (AML) 8 , melanoma 9 , cholangiocarcinoma 10 , and cartilaginous tumors 11 . Even though IDH mut has the same basic effects on the biochemistry and methylome of every cancer in which it has been detected, glioma is the only cancer in which IDH mut is a favorable prognostic marker 6, [12] [13] [14] [15] [16] [17] . The reasons for this are still unclear. In our recently published work, we found that the methylation-dependent suppression of Tissue Factor (TF) contributes to the reduced thrombogenicity and reduced malignancy of IDH mut gliomas, and that
counterparts. Transcriptome differences showed pro-malignant genes that appear to be unique to IDH mut gliomas. However, genes involved in differentiation and immune response were suppressed in all IDH mut cancers. Additionally, IDH mut caused a greater degree of hypermethylation in undifferentiated neural progenitor cells than in mature astrocytes. these data suggest that the extent and targets of IDH mut -induced genomic hypermethylation vary greatly according to the cellular context and may help explain why IDH mut is only a favorable prognostic marker in gliomas.
Epigenetic modifications control gene expression via mechanisms that are highly coordinated throughout the life of a cell. In addition to regulating the development of distinct cell lineages, epigenetic modifications can also promote malignant transformation and cancer progression 1 . Methylation of a CpG site within or near a gene can change its expression, usually by suppressing it. If this happens to a tumor-suppressor gene, oncogenesis may occur The mechanisms by which aberrant methylation occurs, and its consequences in cancer, are becoming better understood. One such mechanism involves point mutations in isocitrate dehydrogenases 1 and 2 (collectively "IDH mut "). These metabolic enzymes normally convert isocitrate into α-ketoglutarate, but mutations in key arginine residues that normally bind isocitrate substrate cause a radical change in enzymatic activity, wherein mutant enzyme converts α-ketoglutarate into D-2-hydroxyglutarate (D2HG) 3 . D2HG then acts as a competitive inhibitor of other enzymes that require α-ketoglutarate as a cofactor, including certain DNA demethylases, leading to genomic CpG hypermethylation and globally altered transcription 4, 5 . IDH mut -induced hypermethylation may lead to suppression of cellular differentiation, thereby prolonging the window in which additional oncogenic "hits" can occur 6 . IDH mut has been identified in a variety of malignancies, but the most common include infiltrative glioma 7 , acute myeloid leukemia (AML) 8 , melanoma 9 , cholangiocarcinoma 10 , and cartilaginous tumors 11 . Even though IDH mut has the same basic effects on the biochemistry and methylome of every cancer in which it has been detected, glioma is the only cancer in which IDH mut is a favorable prognostic marker 6, [12] [13] [14] [15] [16] [17] . The reasons for this are still unclear. In our recently published work, we found that the methylation-dependent suppression of Tissue Factor (TF) contributes to the reduced thrombogenicity and reduced malignancy of IDH mut gliomas, and that Table 1 . Survival plots are depicted in Fig. 1 . IDH mut only had a significant favorable survival advantage in glioma patients (median 79.9 versus 13.3 months, HR = 0.18, 95% CI = 0.14-0.24, P < 0.0001), and was not associated with overall survival in the available AML, cholangiocarcinoma, or melanoma data (Fig. 1). patterns of genomic methylation vary across IDHmut cancers. To determine the methylation profile for each cohort, β-values for CpG sites that met mapping quality thresholds in the TCGA DNA Methylation Liftover Pipeline 20 for all samples within a cancer type were analyzed, yielding 365,092 CpG sites for glioma, 393,152 CpG sites for AML, 379,101 CpG sites for cholangiocarcinoma, and 373,827 CpG sites for melanoma. A CpG site with a mean delta β-value > 0.15 (<0.15) for IDH mut relative to the matching IDH wt cancer, with FDR P < 0.05, was considered to be hypermethylated (hypomethylated). IDH mut was associated with genomic hypermethylation among all cancers, yet hypomethylation was also observed (Fig. 2) . Gliomas showed extensive hypermethylation; of the 365,092 analyzed CpG sites, 70,591 (19%) were hypermethylated in IDH mut glioma compared to IDH wt gliomas, whereas the others ranged between 2-4% (Supplementary Table S1 ). To rule out the possibility that IDH1 wt gliomas are just abnormally hypomethylated relative to other IDH1 wt malignancies, a similar analysis was done directly comparing IDH mut gliomas to the other IDH mut cancers. In this setting, IDH mut gliomas showed much greater levels of hypermethylation when compared with other IDH mut cancers (Supplementary Table S2 ). The number of CpG sites hypermethylated in the other cancers were 13,128 (3%) in AML, 11,763 (3%) in cholangiocarcinoma, and 8,663 (2%) in melanoma relative to each of their IDH wt counterparts ( Fig. 2b-d ). While smaller sample sizes may have contributed to an overall lower frequency of statistically significant findings for AML, cholangiocarcinoma, and melanoma, differences in β-values for IDH mut compared to IDH wt tended to be more extreme across CpG sites for gliomas than for the other cancers, regardless of P-value. Differences in β-values approached 0.8 at the extremes for gliomas, while observed differences in β-values for the other cancers tended to be 0.5 or less (Fig. 2) . Interestingly, IDH mut gliomas also showed the greatest degree of hypomethylation when compared with IDH mut AML, cholangiocarcinoma, and melanoma (Fig. 2) . Overall, these results suggest that the methylation profiles associated with IDH mut vary greatly according to cellular and tissue contexts. To further investigate the unique methylation profiles observed among IDH mut TCGA cancers, methylation sites were grouped into six genomic regions relative to CpG islands: (1) north shelf, (2) north shore, (3) island, (4) south shore, (5) south shelf, (6) open sea 21 . 'Shore' regions immediately flank each CpG island up to 2 kilobases away, 'shelf ' regions extend outwards from the 'shore' up to 2 kilobases away from the shelf, and 'open sea' indicates the rest of the genome. The 'north' region represents the 5′ end, and 'south' the 3′ end. Within each cancer type, IDH mut tumors consistently showed increased methylation across all genomic regions relative to their IDH wt counterparts (Fig. 3) . However, the most striking IDH mut -IDH wt difference in methylation among cancer types Fig. S2 ). This suggests that, while IDH mut is associated with increased CpG methylation across all major genomic regions, the greatest differences occur within CpG islands.
Methylome and transcriptome changes in IDH
mut gliomas are distinct from other IDH mut cancers. Hierarchical cluster analysis of differences in β-values for genes that were hypermethylated in IDH mut compared to IDH wt cancers, in at least one cancer type, highlighted the distinct differential methylation profile for CpG sites between IDH mut and IDH wt subsets across tumor types. In particular, many CpG sites with substantial hypermethylation in gliomas (dark blue) consistently showed far more modest differences in methylation for IDH mut versus IDH wt (yellow) in the other tumors, regardless of statistical significance (Fig. 4A ). Of these CpG sites meeting formal criteria for differential methylation, 56,801 were unique to glioma, and were not identified as differentially methylated in any other IDH mut -IDH wt tumor pairings. Notably, despite smaller sample sizes for AML, cholangiocarcinoma, and melanoma, statistical analyses did identify unique sites of differential methylation in those tumors (6,271 AML; 4,808 cholangiocarcinoma; 3,519 melanoma). Since those CpG sites were not significantly methylated in IDH mut gliomas, even though the glioma cohort was much larger, these results indicate that a great deal of IDH mut -related CpG site methylation is tissue-specific. Only 217 similar CpG sites were hypermethylated across all IDH mut cancers, compared to all IDH wt cancers (Fig. 4B) . Transcriptome comparisons showed similar results, with IDH mut gliomas showing unique alteration of more mRNA transcripts (4,214) than any other tumor type (Fig. 4C,D) . Stratifying IDH mut gliomas into oligodendroglioma and astrocytoma revealed a large amount of similar CpG sites hypermethylated when compared to IDH wt gliomas (Supplemental Fig. S1a,b ). There were some variances in differential gene expression between IDH mut oligodendrogliomas and astrocytomas. Oligodendrogliomas showed unique down regulation of genes linked to angiogenesis, cell proliferation, and integrin binding (Supplemental Fig. S1c ). Hierarchical clustering of methylation sites again demonstrated that, whereas the methylation patterns of IDH mut AML, cholangiocarcinomas, and melanomas were relatively similar, IDH mut gliomas were quite distinct (Fig. 4A) . Glioma showed the greatest IDH mut -IDH wt differential gene expression (4,214), compared to AML (159), cholangiocarcinoma (139), and melanoma (416) (Fig. 4D ). IDH mut gliomas also had the most concordance of genes that were both hypermethylated and differentially expressed when compared with other cancers (Supplementary Table S3 ). www.nature.com/scientificreports www.nature.com/scientificreports/ To better understand how these methylation and transcription differences among IDH mut cancers might impact cell biology, we performed gene set enrichment analyses (GSEA) of genes that were differentially expressed within each pair of IDH mut and IDH wt cancers. Using an FDR-corrected P < 0.05, we found the following differentially expressed genes: 4,691 (glioma); 282 (AML); 246 (cholangiocarcinoma); 758 (melanoma). Compared to IDH wt gliomas, IDH mut gliomas showed increased expression of 1,629 genes and decreased expression of 3,063 genes (Supplementary Spreadsheet). Glioma GSEA of IDH mut and IDH wt tumors revealed a down-regulation of multiple biological processes; most notable were tissue development (GO:0009888), immune response (GO:0006955), angiogenesis (GO:0001525), and cell proliferation (GO:0008283) (Fig. 5a) . GSEA of AML, melanoma, and cholangiocarcinoma showed enrichment of fewer pathways (Fig. 5b-d) , which is likely related to smaller sample sizes and lower statistical power. However, all IDH mut cancers showed suppression of GSEA pathways involved in tissue development (GO:0009888) and immune response (GO:0006955). 22 . R132H IDH1 had a far greater effect on the methylation of undifferentiated NPCs than of mature NHAs, resulting in 87,541 versus 15,976 hypermethylated CpG sites, respectively (Fig. 6a,b) . Basal methylation levels of IDH wt NPCs compared with IDH wt astrocytes showed extensive hypomethylation, suggesting that they may be more amenable to IDH mut ( Supplementary Fig. S6 ). NPCs with IDH mut versus IDH wt showed a much larger shift towards hypermethylation at the 'island' , 'north shore' , and 'south shore' genomic regions when compared to NHAs (Fig. 6c,d ). Since these studies were analyzed retrospectively and performed using separate experimental conditions, caution must be used when interpreting the results. However, these data may suggest that the effect of IDH mut on the methylome not only depends on cellular lineage, but also on the differentiation state and preexisting DNA methylation of the cell. . Follow-up studies showed that, while IDH mut can rarely be found in a variety of cancers, it is most common in glioma, acute myeloid leukemia, cholangiocarcinoma, melanoma, and cartilaginous tumors [7] [8] [9] [10] [11] 24 . This was puzzling, insofar as none of the cancers, or the tissues from which they arise, have any obvious connections with each other. Although IDH mut produces D2HG and causes genomic hypermethylation in each type of cancer, only in gliomas does IDH mut show a consistent, powerful association with prognosis ( Fig. 1) . Guilhamon et al. previously reported on shared signaling pathway alterations in IDH mut cancers 25 , yet to the best of our knowledge, no study has focused on what distinguishes IDH mut gliomas from the others. Our TCGA-based data strongly suggests that IDH mut has a unique effect on the methylome and transcriptome of gliomas relative to other IDH mut cancers, and that this could help explain why IDH mut is only a favorable prognostic marker in gliomas.
Assuming that mutations in dividing cells occur in a more or less stochastic fashion, the study of mutation patterns among cancers raises provocative questions regarding the conditions under which specific alterations exert a positive (or negative) evolutionary advantage. In contrast to TP53, which is frequently mutated in a wide range of cancers, IDH mut is only enriched in a relatively small number of malignancies, none of which bear any clear resemblance to each other. This would seem to indicate that IDH mut , and its D2HG product, are beneficial to cell growth and oncogenesis in only a few settings. Perhaps only a few tissues express wild-type IDH1 and IDH2 in sufficient amounts, or perhaps carbon flux through these enzymes is only strong enough in particular microenvironments, for IDH mut to have a significant effect on metabolism. Wild-type IDH1 and IDH2 normally produce α-ketoglutarate (α-KG) and reduce nicotinamide adenine dinucleotide phosphate (NADPH); the latter then serves as an important antioxidant in the cell 6 . Because IDH mut consumes α-KG and NADPH, some cell types may be better able to compensate for the resultant metabolic deficiencies than others. Since D2HG acts as a competitive inhibitor of certain demethylating dioxygenases that require α-ketoglutarate as a cofactor 6 , the pro-methylating (and pro-oncogenic) effects of IDH mut may depend on the degree to which specific cells express those dioxygenases. And, since a consistent effect of IDH mut is increased genomic methylation, its ability to promote cellular transformation may depend on the patterns of euchromatin and heterochromatin in the cell, which in turn would dictate which regions of the genome are amenable to methylation.
Even among IDH mut cancers, there exists a remarkable preference for certain IDH mut variants according to cancer type. For example, AML has a high proportion of mutations in IDH2, whereas the others are mostly IDH1 (Supplementary Figs S3 and S4 ). This variant still produces D2HG, but IDH2 is localized to the mitochondrial www.nature.com/scientificreports www.nature.com/scientificreports/ matrix, while IDH1 is in the cytosol and peroxisomes 6 . IDH mut glioma is distinct in being the only cancer in the entire body to show enrichment for R132H IDH1 (Supplementary Fig. S4 ). Indeed, R132H IDH1 is so prevalent in gliomas, compared to other variants that are far more common in other IDH mut cancers, it has become standard practice to routinely screen gliomas with an R132H-specific antibody 6 . Yet R132H also appears to be the least efficient producer of D2HG, compared to all other IDH1 and IDH2 variants 26 . This could mean that, in the unique microenvironment of the brain, less D2HG is required for genomic hypermethylation and neoplastic transformation, and that the capacity of glial cells (or glial progenitor cells) to tolerate very high D2HG may be lower than cells elsewhere in the body.
These data also raise the question as to why there is such heterogeneity among CpG methylation sites, particularly in gliomas relative to the other cancers. Even in IDH mut glioma, which shows the greatest extent of CpG hypermethylation compared to its IDH wt counterpart (Fig. 2) , not every CpG site is methylated, and not every gene amenable to methylation-induced silencing is suppressed (Supplementary Table S3) , or IDH mut tumors would probably never form. To reiterate, the D2HG product of IDH mut only inhibits demethylases, and does not directly cause methylation. In addition to tissue-and cell lineage-specific differences in baseline patterns of euchromatin and heterochromatin, there are other downstream mechanisms that determine which CpG sites are methylated and which ones are not. Such mechanisms include targeting of specific CpG islands, as those regions show the greatest cancer-related variations in IDH mut versus IDH wt methylation (Fig. 3) . Prominent among possible mechanisms is cell-specific regulation of DNA methyltransferases, through altered expression, degradation, and complex-mediated targeting of specific CpG sites, which would greatly influence the extent and targets of IDH mut -induced methylation 27 . This could help explain some interesting features of IDH mut gliomas. For example, it is well known that EGFR mutation and/or amplification, which occurs in nearly 50% of IDH wt gliomas, is nearly mutually exclusive with IDH mut 28 . Our data indicate that EGFR is strongly and uniquely hypermethylated in IDH mut gliomas (Supplementary Spreadsheet) ( Supplementary Fig. S5a) ; such silencing would likely diminish any www.nature.com/scientificreports www.nature.com/scientificreports/ selection pressure toward activating EGFR alterations 29, 30 . Conversely, IDH mut gliomas can have PDGFRA amplification 31 , and the PDGFRA gene is mostly hypomethylated in this subset of gliomas ( Supplementary Fig. S5a ) 32 . Similarly, PROM1 is markedly hypermethylated and downregulated only in IDH mut gliomas, not other IDH mut cancers ( Supplementary Fig. S5 ). PROM1 encodes CD133, a well-known marker of tumor-self-renewal and tumor malignancy 33 . One of the phenotypic hallmarks of high CD133-expressing tumors is the ability to grow as patient-derived xenografts in immunocompromised mice-an ability that IDH mut gliomas, but not other IDH mut cancers, typically lack 6 . Analysis of tumor-specific patterns in IDH mut -associated methylation and mRNA transcription yielded other interesting differences, as well as some profound similarities, among IDH mut malignancies (Figs 4 and 5 ). All four IDH mut cancers showed relative suppression of genes involved in tissue development (Fig. 5 ). This has been found to be a consistent effect of IDH mut by multiple laboratories 22, [34] [35] [36] [37] , and helps explain why IDH mut is associated with neoplasia. While neither IDH1 nor IDH2 are classic oncogenes or tumor suppressor genes, and IDH mut is not enough to cause cancer by itself, it may facilitate oncogenesis by extending the window of vulnerability in which additional pro-oncogenic mutations can arise, such as those involving TP53 in IDH mut astrocytomas 6 . Another common feature of IDH mut cancers is the downregulation of genes associated with immune response (Fig. 5) . This is increasingly becoming a recognized feature of IDH mut gliomas [38] [39] [40] [41] ; our data show that this applies to all IDH mut malignancies, with implications for the efficacy of immune-based therapies in this subset of cancers.
Studies that have demonstrated a direct causal link between IDH mut , its D2HG product, and genomic hypermethylation have often done so by inserting one of the IDH mut variants into IDH wt cells, then passaging those cells multiple times and assessing their methylation via the Infinium 450K array. However, the choice of cell model has varied greatly from group to group. Data from two of those models, one expressing R132H IDH1 in differentiated, immortalized human astrocytes 5 , and the other expressing the same mutation in less differentiated neural progenitor cells 22 , for the same number of passages apiece, demonstrate that the ability of R132H IDH1 www.nature.com/scientificreports www.nature.com/scientificreports/ to promote methylation is much greater in less differentiated cells (Fig. 6 ). This is consistent with the prevailing thinking, based on patient data, that IDH mut occurs at a very early step in oncogenesis, in cells that have not yet fully differentiated 42 . Whether this window of sensitivity to IDH mut is due to greater amounts of open euchromatin in earlier stages of differentiation, and/or other downstream modulators as discussed above, is not yet clear. But these data do suggest that the choice of cell differentiation state, as well as cell lineage, could greatly impact the results generated in experimental IDH mut research. It may also help explain conflicting results in the literature, including why some investigators have found that IDH mut impairs cancer cell malignancy, whereas others have reported no difference, or even that IDH mut enhances malignant behavior. The same holds for preclinical studies of IDH mut inhibitors, in which some have reported responses to targeted inhibition, whereas others have not. Finally, these data raise the question as to why certain settings, in which IDH mut showed the greatest amount of hypermethylation, also showed increased hypomethylation relative to matched IDH wt tumors (Figs 2a and 6b ). To date, the IDH mut literature has focused on hypermethylation, but these data suggest that there may be another aspect to the effects of IDH mut on the genome, perhaps in the form of increased methylation turnover, or alteration of chromatin structure via IDH mut -induced histone methylation, leading to altered accessibility of DNA for methylation.
There are some limitations to this study, including the comparatively fewer numbers of non-glial cancers with IDH mut . However, our analyses showed CpG sites and mRNA transcripts that were specifically altered in non-glioma IDH mut cancers, but not in gliomas (Figs 4 and 5 Supplementary Tables S1, S2 , and Fig. S2 ). The focus of this project was on TCGA cancers, which does not include chondrosarcomas, another cancer in which IDH mut is frequently seen 11 . Finally, histone 
Methods
Analysis of DNA methylation. DNA methylation data from Illumina Human Methylation 450K arrays were downloaded from the Cancer Genome Atlas using the TCGAWorkflow and TCGAbiolinks R packages 43, 44 . Legacy data with methylation levels expressed as β-values were downloaded during October 2018 20 . Primary solid tumor data were downloaded for glioma and cholangiocarcinoma. Primary solid tumor and metastatic tumor data were downloaded for melanoma.
CpG genomic region methylation analysis. CpG sites were mapped to regions (North Shelf, North Shore, Island, South Shore, South Shelf, Open Sea) using the IlluminaHumanMethylation450kanno.ilmn12.hg19 R package.
Analysis of gene expression. Transcriptome profiles from the Illumina HiSeq platform were downloaded from The Cancer Genome Atlas using the TCGAWorkflow and TCGAbiolinks R packages 43, 44 . Harmonized data with gene expression levels quantified as counts were downloaded during October 2018. Data were normalized according to the 'gcContent' method 45 . Primary solid tumor data were downloaded for glioma and cholangiocarcinoma. Primary solid tumor and metastatic tumor data were downloaded for melanoma.
Gene ontology analysis. Gene Ontology (GO) analyses were conducted using differentially expressed genes comparing IDH mut versus IDH wt within each cancer type. The cutoff value for the differentially expressed genes was set P < 0.05. The web-based application Metascape (http://www.metascape.org) was used to determine significantly enriched GO biological processes 46 . The Metascape analysis was performed using the default settings.
Gene set enrichment analysis (GSEA) and network construction. Mean differential gene expression analysis was conducted on IDH mut and IDH wt cancers using the gene set enrichment analysis (GSEA) Desktop v3.0 software (http://www.software.broadinstitute.org/gsea/index.jsp). The number of gene permutations was set to 1,000. The gene-sets were derived from the Broad institute's Molecular Signatures Database (MSigDB) 47 . Network data visualization and analysis were performed with Cytoscape v3.5.1 software (http://www.cytoscape. org) and with the EnrichmentMap plugin application 48, 49 . EnrichmentMap threshold settings: false-discovery rate (FDR) q-value < 0.05; overlap coefficient cutoff = 0.5; P-value < 0.05. The functional networks of nodes that represent generic function were determined using the Cytoscape AutoAnnotate application 50 .
Meta-analysis of astrocyte and neural progenitor cell methylation. For the analysis comparing genome methylation in IDH mut astrocytes and neural progenitor cells data were downloaded from the Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) using data sets GSE30339 and GSE94962 5, 22 . In brief, immortalized human astrocytes were modified to express the IDH1 (R132H) mutation, cultured for 15 passages, and DNA extracted for methylation analysis. Illumina Methylation 450 K data from these data sets were then analyzed using the same approach described in the analysis of DNA methylation methods section. statistical analysis. Differential methylation was evaluated according to Wilcoxon rank sum tests with false discovery rate (FDR) correction. Differential gene expression was evaluated using the edgeR package with FDR correction 51 . Venn diagrams and heatmaps were used to visualize pairwise comparisons of methylation and gene expression.
Data Availability
The results shown here are in part based upon data generated by the TCGA Research Network (http://cancergenome.nih.gov/). Methylation profiles of astrocytes and neural progenitor cells was downloaded from the GEO (http://www.ncbi.nlm.nih.gov/geo/) using data set GSE30339 and GSE94962.
